Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.22 MXN
−511.15 M MXN
0.00 MXN
125.75 M
About Atossa Therapeutics, Inc.
Sector
CEO
Steven C. Quay
Headquarters
Seattle
Website
Founded
2008
FIGI
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where ATOS is featured.
Frequently Asked Questions
The current price of ATOS is 21.20 MXN — it has increased by 4.95% in the past 24 hours. Watch ATOSSA THERAPEUTICS, INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange ATOSSA THERAPEUTICS, INC stocks are traded under the ticker ATOS.
ATOS stock has fallen by −6.03% compared to the previous week, the month change is a −12.58% fall, over the last year ATOSSA THERAPEUTICS, INC has showed a 69.06% increase.
We've gathered analysts' opinions on ATOSSA THERAPEUTICS, INC future price: according to them, ATOS price has a max estimate of 141.40 MXN and a min estimate of 80.80 MXN. Watch ATOS chart and read a more detailed ATOSSA THERAPEUTICS, INC stock forecast: see what analysts think of ATOSSA THERAPEUTICS, INC and suggest that you do with its stocks.
ATOS stock is 5.00% volatile and has beta coefficient of 2.31. Track ATOSSA THERAPEUTICS, INC stock price on the chart and check out the list of the most volatile stocks — is ATOSSA THERAPEUTICS, INC there?
Today ATOSSA THERAPEUTICS, INC has the market capitalization of 2.61 B, it has decreased by −3.93% over the last week.
Yes, you can track ATOSSA THERAPEUTICS, INC financials in yearly and quarterly reports right on TradingView.
ATOSSA THERAPEUTICS, INC is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ATOS earnings for the last quarter are −1.18 MXN per share, whereas the estimation was −1.18 MXN resulting in a 0.00% surprise. The estimated earnings for the next quarter are −1.21 MXN per share. See more details about ATOSSA THERAPEUTICS, INC earnings.
ATOSSA THERAPEUTICS, INC revenue for the last quarter amounts to 0.00 MXN, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ATOS net income for the last quarter is −142.46 M MXN, while the quarter before that showed −110.95 M MXN of net income which accounts for −28.40% change. Track more ATOSSA THERAPEUTICS, INC financial stats to get the full picture.
No, ATOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 12.00 employees. See our rating of the largest employees — is ATOSSA THERAPEUTICS, INC on this list?
Like other stocks, ATOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ATOSSA THERAPEUTICS, INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ATOSSA THERAPEUTICS, INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ATOSSA THERAPEUTICS, INC stock shows the sell signal. See more of ATOSSA THERAPEUTICS, INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.